Business
Johnson & Johnson’s DARZALEX® (daratumumab) becomes the first oncology injectable approved for administration by patients or caregivers
Landmark decision by CHMP grants approval for self or caregiver administration for patients living with multiple myeloma1 Milestone is a testament to ten years of daratumumab experience and innovation, continuing to transform multiple myeloma care BEERSE, BELGIUM, March 27, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted approval for a Type II variation to the labelling fo
About this update from Johnson & Johnson
[{"type":"image","alt":"Johnson & Johnson EMEA","displaySize":"","headline":null,"caption":"Johnson & Johnson EMEA","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":57,"url":"https://media.zenfs.com/en/globenewswire.com/162e5e4bfb9f63ed2555dd2e00c88cf1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/39J5V2CV.1XQgEYJw1LiLw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTgw/https://media.zenfs.com/en/globenewswire.com/162e5e4bfb9f63ed2555dd2e00c88cf1","width":300,"height":57}},"lazy":false},{"type":"text","content":"Landmark decision by CHMP grants approval for self or caregiver administration for patients living with multiple myeloma1","length":121,"tagName":"p"},{"type":"text","content":"Milestone is a testament to ten years of daratumumab experience and innovation, continuing to transform multiple myeloma care","length":125,"tagName":"p"},{"type":"text","content":"BEERSE, BELGIUM, March 27, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted approval for a Type II variation to the labelling for DARZALEX® (daratumumab) subcutaneous (SC) formulation. The label update enables patients living with multiple myeloma or their caregivers to administer daratumumab from the fifth dose, if determined to be appropriate by their healthcare professional and following proper training.1 This landmark decision makes daratumumab the first oncology injectable approved for self-administration in Europe.1","length":655,"tagName":"p"},{"type":"text","content":"Offering greater flexibility in careWith this label update, patients and their healthcare professionals can work together to decide the most suitable choice of administration.1 It applies to all ten therapeutic indications of daratumumab SC for multiple myeloma, smouldering multiple myeloma and light chain (AL) amyloidosis.","length":331,"tagName":"p"},{"type":"text","content":"“For many patients living with multiple myeloma, treatment can involve frequent hospital visits and the challenge of fitting care around everyday life,” said Thomas Lund, M.D., Ph.D., Head of Hematological Section, Department of Medicine, Vejle Hospital, Department of Regional Health Research, University of Southern Denmark.* “The possibility for self-administration of daratumumab subcu...